A study of a new cell therapy for advanced liver cancer
Part of Cancer clinical trials.
This trial tests a new treatment called OriC902 for people with advanced liver cancer (HCC) that has not responded to standard therapies. The treatment uses special immune cells designed to target a protein called GPC3 found on cancer cells. The goal is to see if this approach can help shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced liver cancer that cannot be treated with local therapies or has returned after such treatments.
- Standard treatments (like targeted therapy, immunotherapy, or chemo) must have stopped working, with tumor growth confirmed by scans.
- Your liver function must be well enough (Child-Pugh A or B7 without confusion).
- You must be able to collect blood cells for the treatment through a process called apheresis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.